Bridgewater Associates’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
Other funds holding HAE
AI
Bridgewater Associates's HAE Position: Q2 2026 in Review
Bridgewater Associates increased its Haemonetics (HAE) stake by 23% in Q2 2026, buying an estimated $729K and bringing the position to 59,733 shares worth $4.48M. The position accounts for 0.02% of the portfolio, ranked #499.
Bridgewater Associates first reported a position in HAE in Q2 2021 and has held it in 20 quarters since. The position peaked at $6M in Q3 2022. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Bridgewater Associates held 59,733 shares of Haemonetics worth $4.48M as of Q2 2026.
- Bridgewater Associates bought 11,356 Haemonetics shares in Q2 2026, an estimated $729K.
- Haemonetics made up 0.02% of Bridgewater Associates's portfolio in Q2 2026, its #499 holding.
- Bridgewater Associates first reported a position in Haemonetics in Q2 2021 and has held it in 20 quarters since.
- Bridgewater Associates's Haemonetics position peaked at $6M in Q3 2022.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.